Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMV Vaccine Alone or with Toripalimab-tpzi in Recurrent HNSCC
NCT07898124Phase 1Recruiting
- Sponsor
- Metaclipse Therapeutics
- Start
- Oct 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of tumor membrane vesicle vaccine in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Metaclipse Therapeutics. Primary endpoints: Dose-Limiting Toxicities in Phase 1a at 7 weeks, Treatment-Emergent Adverse Events and Serious Adverse Events in Phase 1a at 8 weeks and 5 more. Started Oct 2026; status: recruiting.
02
Drugs
tumor membrane vesicle vaccine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07898124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07898124.